Financial statements Tabiplast
Balance sheet data of TABIPLAST
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
|---|---|---|---|---|---|---|
| Total assets | 34 047 667,33 | 40 581 719,67 | 49 291 443,36 | 51 586 871,14 | 52 079 654,32 | 48 660 201,23 |
| A. Fixed assets | 18 370 486,85 | 26 937 828,66 | 25 044 536,86 | 27 034 118,45 | 28 411 140,85 | 21 663 385,86 |
| B. Current assets | 15 677 180,48 | 13 643 891,01 | 24 246 906,50 | 24 552 752,69 | 23 668 513,47 | 26 996 815,37 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 34 047 667,33 | 40 581 719,67 | 49 291 443,36 | 51 586 871,14 | 52 079 654,32 | 48 660 201,23 |
| A. Equity | 17 965 227,48 | 18 088 175,96 | 19 246 711,55 | 20 200 101,87 | 21 340 160,52 | 20 195 386,81 |
| B. Liabilities and provisions for liabilities | 16 082 439,85 | 22 493 543,71 | 30 044 731,81 | 31 386 769,27 | 30 739 493,80 | 28 464 814,42 |
| I. Long-term liabilities | 2 216 092,36 | 5 005 389,82 | 4 033 765,16 | 4 159 218,54 | 5 217 654,64 | 3 144 969,01 |
| II. Short-term liabilities | 13 065 785,06 | 16 690 098,69 | 25 071 742,85 | 25 709 112,67 | 23 704 944,41 | 24 078 271,90 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.
AD
AD